Your session is about to expire
← Back to Search
Beta Blocker
Metoprolol Succinate for Long COVID (PEACE Trial)
Phase < 1
Waitlist Available
Led By David Landers, MD
Research Sponsored by Hackensack Meridian Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks from baseline
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a potential treatment for the post-acute COVID 19 syndrome (PASC). The symptoms of this condition are highly variable and often extraordinarily debilitating, and as of July 2021 it qualifies as a disability under the Americans with Disabilities Act. The trial is testing whether the treatment can help patients who have these symptoms and who have had COVID-19.
Who is the study for?
This trial is for individuals aged 18-40 who've recovered from COVID-19 but experience shortness of breath and rapid heartbeat with minimal activity, lasting 3-12 months. They must have normal heart function, blood counts, and thyroid levels, without chronic lung issues or other conditions like dysautonomia.
What is being tested?
The study tests Metoprolol Succinate's effectiveness in treating long-term symptoms after COVID-19 recovery—specifically difficulty breathing on exertion and associated fast heartbeat.
What are the potential side effects?
Metoprolol may cause dizziness, fatigue, depression, shortness of breath during exercise, insomnia, or unusual dreams. It can also slow down the heart rate too much.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks from baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks from baseline
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in 6 minute walk test at the end of treatment period
Change in Zva measurement at the end of treatment period
Secondary study objectives
Heart failure
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Study arm - Metoprolol Succinate.Experimental Treatment1 Intervention
The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum dose of 400 mg po daily.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Metoprolol Succinate
2023
Completed Phase 4
~2030
Find a Location
Who is running the clinical trial?
Hackensack Meridian HealthLead Sponsor
135 Previous Clinical Trials
30,321 Total Patients Enrolled
David Landers, MDPrincipal InvestigatorHackensack Meridian Health
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a fever or an infection.You are currently being treated for a pre-existing condition that causes fainting or low blood pressure.Your Zva score is higher than 3.5 based on a heart ultrasound test.You have an overactive thyroid.Your hemoglobin and hematocrit levels are within the normal range according to lab tests.You are currently pregnant.You are currently taking beta blocker medications.You should be between 18 and 40 years old and have been experiencing shortness of breath during physical activity for 3 to 12 months.You have recently recovered from a positive COVID-19 test.You experience fast heart rate and/or shortness of breath with very little activity, different from how you felt before getting COVID-19.You have a normal chest x-ray.Show that the main reason for your rapid heart rate is from appropriate physical activity or sinus tachycardia.You had an abnormal heads up tilt test.You are currently going through withdrawal from alcohol, drugs, or medications.You have low levels of red blood cells.You have very low blood volume.You have gotten better from COVID-19 and your symptoms have improved a lot.Your heart's pumping ability is greater than 50% as measured by a heart ultrasound.You have a history of long-term lung problems or reactive airway syndrome.Your thyroid-stimulating hormone (TSH) levels are within the normal range according to lab tests.
Research Study Groups:
This trial has the following groups:- Group 1: Study arm - Metoprolol Succinate.
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger